RxDoctor Payments Data

Vicki Hansen

Family · Maquoketa, IANPI 1124560206

Payments from drug & device makers

$3,186in general payments, 2019–2025

Across 178 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$519
  • AstraZeneca$386
  • Novo Nordisk$343
  • Amgen$312
  • Lilly USA, LLC$252
  • AbbVie$204
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,186 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$135,997
Medicare patients
207
Services billed
6,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$35,796
FarxigaDapagliflozin Propanediol19$25,371
EliquisApixaban18$21,518
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,313
Memantine Hcl16$1,700
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,513
Omeprazole131$1,461
Atorvastatin Calcium162$1,337
Ventolin HfaAlbuterol Sulfate18$1,029
Potassium Chloride55$887
Gabapentin36$863
Pravastatin Sodium45$695
Duloxetine Hcl25$682
Albuterol Sulfate HfaAlbuterol Sulfate28$653
Levothyroxine Sodium120$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$343$35,79627 claims
AstraZenecaFarxiga, Breztri Aerosphere$386$35,68435 claims
PfizerEliquis$519$21,51818 claims
AbbVieSynthroid$204$52014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.

Other family in Maquoketa

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →